Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A1MX
|
|||
| Former ID |
DIB000271
|
|||
| Drug Name |
Bapineuzumab
|
|||
| Synonyms |
AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [1], [2] | |
| Company |
Elan Corp plc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6930). | |||
| REF 2 | Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):322-33. | |||
| REF 3 | Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.